Specifically, sodium-glucose co-transporter type 2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RA) exhibited beneficial effects in preventing cardiovascular events in T2D, thus confirming their value as disease-modifying drugs (DMDs) [27]. Here, SLC5A2 is linked to type 2 diabetes mellitus.